Lakefront Biotherapeutics NV (LKFT) Stock Forecast
LKFT analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.17 / 5 from 6 analysts
- Price target
- $30.29 average of analyst targets
- Upside to target
- +1.3% from the latest close
- Next earnings
- —
- 52-week range
- $26.08 – $34.64
LKFT analyst ratings
6 analystsNumber of analysts at each rating.
LKFT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LKFT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.23 | $0.23 | $0.23 | −$0.18 | +229.2% | 1 |
| Current fiscal year (2026) | −$0.71 | −$0.71 | −$0.71 | $10.21 | −107.0% | 1 |
| Next fiscal year (2027) | −$1.06 | −$1.75 | −$0.37 | −$0.71 | −49.3% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LKFT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $41.2M | $7.5M | $74.8M | −42.1% | 2 |
| Current fiscal year (2026) | $117.2M | $18.6M | $299.3M | −89.5% | 3 |
| Next fiscal year (2027) | $84.6M | $27.8M | $212.8M | −27.8% | 4 |
LKFT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LKFT revenue: reported and forecast
LKFT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.31 | −$0.49 | $0.23 | $0.23 | $0.23 | −117.6% | 0 up · 0 down |
| Current fiscal year (2026) | −$2.29 | −$2.29 | −$13.24 | −$0.71 | −$0.71 | −69.1% | 1 up · 0 down |
| Next fiscal year (2027) | −$2.33 | −$1.72 | −$1.06 | −$1.06 | −$1.06 | −54.5% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LKFT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LKFT beat in 9 of 11.
What analysts expect from LKFT
6 analysts cover Lakefront Biotherapeutics; their consensus rating is hold (3.17 on a 1–5 scale, where 5 is a strong buy). The average price target is $30.29, 1.3% above the latest close of $29.90. Analysts expect earnings of −$0.71 per share for 2026, −107.0% from a year earlier. For 2027 the average estimate is −$1.06 per share on revenue of $84.6 million. Lakefront Biotherapeutics beat the EPS estimate in 9 of the last 11 quarters.
Related: LKFT income statement, LKFT key metrics, LKFT chart. See the LKFT stock overview for the latest quote and news.
LKFT forecast FAQ
What is Lakefront Biotherapeutics's price target?
The average analyst price target for Lakefront Biotherapeutics is $30.29, 1.3% above the latest close of $29.90.
Is Lakefront Biotherapeutics a buy, hold or sell?
Of 6 analysts covering Lakefront Biotherapeutics, 1 rate it a strong buy, 1 a buy, 3 a hold, 0 a sell and 1 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Lakefront Biotherapeutics's EPS forecast?
Analysts forecast −$0.71 per share for 2026 (range −$0.71 to −$0.71); for 2027 the estimate is −$1.06.
What is Lakefront Biotherapeutics's revenue forecast?
The average revenue estimate for 2026 is $117.2 million, growth of −89.5%; for 2027 it is $84.6 million.
Does Lakefront Biotherapeutics usually beat earnings estimates?
Lakefront Biotherapeutics reported EPS at or above the analyst estimate in 9 of the last 11 quarters.